Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global RNA Drugs Market Strategic Outlook, 2021-2031: Delivery, Value Chain, and Competition | 13%-15% CAGR Unlocks Pipeline and Manufacturing Opportunities"RNA Drugs Market Strategic Analysis: Delivery Innovations, Value Chain, and Competitive Dynamics" has been added to ResearchAndMarkets.com's offering.
- Global Oligonucleotide Synthesis Market Forecast to 2031 | Market to Reach US$32.72 Billion at 17.4% CAGR as RNA Therapeutics and Molecular Diagnostics Scale"Oligonucleotide Synthesis Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.
- Artificial Intelligence (AI) in Drug Discovery Market - Global Strategic Insights and Forecast, 2026-2031 | 31.7% CAGR Drives a USD 3.97 Billion Opportunity by 2031"Artificial Intelligence in Drug Discovery Market - Strategic Insights and Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
- DuLac Farmaceutici Takes Next Step in U.S. Retail Growth Following ECRM MeetingsBoca Raton, Florida Monday Oct 12, 2026 @ 5:00 AM Eastern — DuLac Farmaceutici is following up with prospective retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. This event is marking another step in the Italian pharmaceutical company's effort to build a broader U.S. retail presence beyond its established Amazon business. The event provided an opportunity to discuss DuLac’s Italian-developed portfolio with buyers across health, specialty, food, drug and mass retail channels. The company is now continuing those conversations to explore product assortment and distribution opportunities in the United States. DuLac’s portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines. The portfolio reflects the company’s Italian manufacturing expertise, botanical formulation capabilities, and more than 30 years of pharmaceutical industry experience. Building on an Existing E-Commerce Presence DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi. Customer feedback provides an additional point of reference for prospective partners: The company’s Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars, offering prospective partners a reference point for consumer feedback as they evaluate the portfolio. "Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.” Italian Expertise Behind the Portfolio During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies. The company’s European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning and the requirements for a potential launch. U.S. Retail and Distribution Opportunities Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit and distribution opportunities, while building on its existing U.S. e-commerce presence. The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market. About DuLac Farmaceutici DuLac Farmaceutici is an Italian pharmaceutical company specializing in dermo-cosmetic products developed through pharmaceutical-grade manufacturing standards. Built on more than 30 years of pharmaceutical industry expertise, the company combines botanical innovation, advanced extraction technologies, and modern manufacturing to create Italian-developed products for international markets. DuLac products are developed and manufactured in Italy using rigorous quality and sustainability standards. Learn more at DuLac Farmaceutici USA, through the company's Amazon Storefront, and on OneLavi.
- Micot Pharma Debuts MT200605 Huntington's Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative DiseasesHong Kong, Oct 12, 2026 - The International Congress of Parkinson's Disease and Movement Disorders (MDS 2026) was held in Seoul, South Korea, from October 4 to 8, 2026. Micot Pharma (2335.HK) presented, for the first time in an electronic poster, nonclinical findings in Huntington's disease (HD) and Phase I clinical results in healthy volunteers for its independently developed drug candidate MT200605. Together with previously announced positive Phase II data in acute ischemic stroke (AIS), these findings are beginning to establish a development path for this small-molecule tropomyosin receptor kinase B (TrkB) agonist from acute brain injury to neurodegenerative diseases. On-site photo from the MDS 2026 Congress Organized by the International Parkinson and Movement Disorder Society, the MDS Congress is one of the largest and most influential international scientific meetings in the field. The selection of MT200605's Huntington's disease research for presentation signals recognition by the international scientific community of its clinical value in neurodegenerative diseases. For Micot Pharma, the significance of this appearance extends beyond the poster presentation itself. It brings MT200605's progress in clinical development for stroke into an international forum for scientific exchange on movement disorders and neurodegenerative diseases. It also gives the market a more complete view of the development program: animal-model findings and Phase I data in healthy volunteers are available for the HD program, Phase II topline results are available for AIS, and the TrkB mechanism provides the central link between research in acute brain injury and chronic neurodegenerative diseases. On-site photo from the MDS 2026 Congress MT200605 Explores Disease-Modifying Potential in Huntington's Disease through Motor Improvement and Preservation of Brain Structure Huntington's disease is an inherited, progressive neurodegenerative disorder. Patients gradually develop chorea, cognitive decline, and psychiatric and behavioral disturbances, eventually becoming fully dependent on care. Current treatments primarily manage symptoms; no treatment can yet halt or reverse disease progression. Protecting neurons and preserving neurological function are therefore important areas of research. The publicly available MDS 2026 abstract reports that MT200605 improved motor coordination and attenuated whole-brain, cortical, and striatal atrophy in transgenic HD mice. The study also found that levels of the striatal neuronal marker DARPP-32 were maintained and that aggregation of mutant huntingtin protein (mHTT) in the cortex was reduced. In vitro experiments showed activation of TrkB and downstream AKT signaling, as well as enhanced mitochondrial adenosine triphosphate (ATP) production in HD cells. The value of these findings lies in the converging evidence from behavioral, imaging, and cellular pathology measures. Beyond improved motor performance, changes in brain atrophy and aggregation of the disease-causing protein provide a more concrete basis for investigating a potential disease-modifying effect. The poster also presented results from a Phase I clinical study of MT200605 in healthy adults. The study used a single-center, randomized, double-blind, placebo-controlled design and comprised single ascending dose (SAD) and multiple ascending dose (MAD) stages. No serious adverse events, deaths, or withdrawals due to adverse events were reported. Drug-related adverse events were all mild and self-limiting. Pharmacokinetic results showed that drug exposure increased with dose, with no appreciable accumulation after multiple doses and an overall predictable pharmacokinetic profile. These results provide a safety and pharmacokinetic foundation for subsequent clinical studies in patient populations. TrkB Signaling Provides a Basis for Extending Development from Acute Brain Injury to Neurodegenerative Diseases A defining feature of MT200605's mechanism is its pharmacological modulation of the brain-derived neurotrophic factor (BDNF)/TrkB neurotrophic signaling pathway. This pathway contributes to neuronal survival, synaptic maintenance, and mitochondrial stability, providing an important biological basis for neuroprotection and the preservation of function. MT200605's pharmacological design reportedly combines agonism of the BDNF/TrkB pathway with attenuation of oxidative stress and relief of microcirculatory impairment caused by calcium ion-induced contraction of vascular smooth muscle. The development rationale is to explore more comprehensive neuroprotection by intervening in multiple components of the injury process. From a mechanistic perspective, targeting TrkB provides a rationale for extending MT200605's development into chronic neurodegenerative diseases. Although the pathogenic processes of stroke and Huntington's disease differ substantially, neuronal injury, loss of function, and insufficient neurotrophic support offer points of entry for research across diseases. The findings across multiple measures in the HD model provide new experimental support for this direction. Positive Phase II Stroke Results Show a Significant Reduction in Disability and Potential for Renal Protection MT200605 has completed a Phase II clinical trial in acute ischemic stroke. The multicenter, randomized, double-blind, placebo-controlled study enrolled 360 participants. The primary efficacy endpoint was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days after stroke onset. Results disclosed by the company show that the proportions of patients achieving favorable functional outcomes in both the medium- and high-dose groups were higher than in the placebo group, demonstrating a treatment advantage rarely seen among drugs in this class. For the high-dose group, achieving an mRS score of 0-1 corresponded to an increase of more than 100% in the odds of functional recovery versus placebo, as reflected by the odds ratio (OR). In terms of clinical benefit, approximately one additional patient moved from "requiring assistance" to "being able to live largely independently" for every six patients treated. Over decades of neuroprotective drug development, agents demonstrating such a marked difference in functional outcomes versus placebo in a randomized controlled trial have been exceptionally rare. The difference between the high-dose group and placebo was statistically significant, and the study showed a clear dose-response relationship. The study also observed a trend toward early neurological recovery in the high-dose group, with no serious adverse events related to the investigational drug. For stroke-associated acute kidney injury (AKI), the study also observed a trend toward a dose-dependent reduction in incidence, providing exploratory clinical evidence for further research into the mechanism of "dual brain and kidney protection." The design rationale for this dual protection was validated in the Phase II trial: MT200605 significantly reduced disability and showed the potential to lower AKI incidence in patients with AIS in a dose-dependent manner. AKI incidence in the high-dose group was more than 80% lower than in the placebo group. This result addresses the existing therapeutic gap in preventing AKI in patients with AIS. Neurological Recovery and Combined Brain and Kidney Protection Offer the Potential to Fill a Therapeutic Gap Currently, no neuroprotective drug for AIS has a Class I recommendation supported by Level A evidence in Chinese clinical guidelines. Most marketed agents have Class II recommendations supported by Level B evidence. Mainstream neuroprotective drugs in China include butylphthalide, edaravone, and edaravone dexborneol. Their mechanisms are generally limited to blocking injury through one or two targets, without a mechanistic design that simultaneously promotes neural repair, and none has demonstrated a statistically significant difference in long-term functional outcomes such as those measured by the mRS. Butylphthalide has a research foundation in neuroprotection involving multiple targets. The randomized BAST trial enrolled 1,216 patients with acute ischemic stroke who received intravenous thrombolysis and/or endovascular treatment. Favorable functional outcomes at 90 days were achieved by 56.7% of patients in the butylphthalide group and 44.0% in the placebo group. The endpoint used different mRS thresholds according to baseline stroke severity, providing evidence for combining neuroprotection with reperfusion treatment. Edaravone's principal pharmacological action is free radical scavenging, while edaravone dexborneol extends antioxidant and anti-inflammatory intervention through a combination formulation. In the Phase III TASTE study involving 1,165 patients, the proportions achieving an mRS score of ≤1 at 90 days were 67.18% in the edaravone dexborneol group and 58.97% in the edaravone group. Edaravone dexborneol was superior to edaravone, with a statistically significant difference. The research indicates that MT200605's differentiation should not be reduced to a simple numerical comparison of efficacy with existing agents. The more relevant question to follow is whether the TrkB neurotrophic pathway can translate the functional outcome signals observed in patients with AIS into clinical benefits in chronic neurodegenerative diseases. As a first-in-class (FIC) investigational drug, MT200605 has completed clinical proof of concept. Its effect size far exceeds that of other neuroprotective agents, and it has the potential to become the first treatment in this field to receive high-level recommendations as a first-line option in both Chinese and international clinical guidelines. Another "silent killer" can emerge following stroke: acute kidney injury (AKI). Approximately 19% of patients with AIS develop AKI, and the risk of in-hospital death among patients with AKI is around two to three times that of patients without AKI. Product labeling for approved mainstream neuroprotective drugs advises caution or contraindicates use in patients with impaired renal function or severe renal failure. As a result, precisely those stroke patients facing a higher risk of death are excluded from treatment. A further reason to follow MT200605 is that, alongside the positive signals for 90-day functional outcomes in the AIS Phase II trial, the company has disclosed a new area of investigation: renal protection after stroke. According to Micot Pharma's announcement, AKI incidence in the high-dose group was approximately 80% lower than with placebo in the Phase II data. This means that MT200605 is currently the world's only investigational neuroprotective drug with the potential to specifically prevent and treat post-stroke AKI, and the only agent in this class that could potentially be approved and used with a "renal protection" claim in its labeling. MT200605's ability to protect both the brain and kidneys is closely linked to its distinctive mechanism of action. TrkB receptors are expressed not only in brain tissue but also in renal podocytes, renal tubular epithelial cells, and the juxtaglomerular apparatus. Their activation can stabilize the podocyte cytoskeleton, inhibit renal tubular epithelial cell apoptosis by counteracting endoplasmic reticulum stress through PI3K/AKT signaling, and activate antioxidant defenses through the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2), an important target of neuroprotective drugs. A single molecule protects two organs affected by stroke. The protective pathways in the brain and kidneys share the core PI3K/AKT signaling cascade, disrupting at its origin the vicious cycle of brain injury leading to AKI, worsening renal function, and further aggravation of brain injury. The MDS presentation and AIS Phase II topline results are therefore complementary. The former expands MT200605's international scientific visibility and the scope of its HD research, while the latter provides a translational foundation in patient functional outcomes. For a biopharmaceutical company focused on innovative medicines, a development program built around one mechanism, multiple disease settings, and progressively accumulating evidence at different levels often has greater scope for expansion than an early-stage narrative centered on a single indication. Conclusion In the near term, MDS 2026 has given Micot Pharma an international platform to present its research in movement disorders. Over the medium to long term, the program's value as a platform will depend on whether the company can continue to use verifiable clinical data to translate the potential of the TrkB mechanism across different disease settings into benefits for patients. For the capital markets, this is the central rationale for continuing to follow MT200605's development.
- Micot Pharma Debuts MT200605 Huntington's Disease Research in a Poster Presentation at MDS 2026 and Expands Development into Neurodegenerative DiseasesHong Kong, Oct 12, 2026 - The International Congress of Parkinson's Disease and Movement Disorders (MDS 2026) was held in Seoul, South Korea, from October 4 to 8, 2026. Micot Pharma (2335.HK) presented, for the first time in an electronic poster, nonclinical findings in Huntington's disease (HD) and Phase I clinical results in healthy volunteers for its independently developed drug candidate MT200605. Together with previously announced positive Phase II data in acute ischemic stroke (AIS), these findings are beginning to establish a development path for this small-molecule tropomyosin receptor kinase B (TrkB) agonist from acute brain injury to neurodegenerative diseases. On-site photo from the MDS 2026 Congress Organized by the International Parkinson and Movement Disorder Society, the MDS Congress is one of the largest and most influential international scientific meetings in the field. The selection of MT200605's Huntington's disease research for presentation signals recognition by the international scientific community of its clinical value in neurodegenerative diseases. For Micot Pharma, the significance of this appearance extends beyond the poster presentation itself. It brings MT200605's progress in clinical development for stroke into an international forum for scientific exchange on movement disorders and neurodegenerative diseases. It also gives the market a more complete view of the development program: animal-model findings and Phase I data in healthy volunteers are available for the HD program, Phase II topline results are available for AIS, and the TrkB mechanism provides the central link between research in acute brain injury and chronic neurodegenerative diseases. On-site photo from the MDS 2026 Congress MT200605 Explores Disease-Modifying Potential in Huntington's Disease through Motor Improvement and Preservation of Brain Structure Huntington's disease is an inherited, progressive neurodegenerative disorder. Patients gradually develop chorea, cognitive decline, and psychiatric and behavioral disturbances, eventually becoming fully dependent on care. Current treatments primarily manage symptoms; no treatment can yet halt or reverse disease progression. Protecting neurons and preserving neurological function are therefore important areas of research. The publicly available MDS 2026 abstract reports that MT200605 improved motor coordination and attenuated whole-brain, cortical, and striatal atrophy in transgenic HD mice. The study also found that levels of the striatal neuronal marker DARPP-32 were maintained and that aggregation of mutant huntingtin protein (mHTT) in the cortex was reduced. In vitro experiments showed activation of TrkB and downstream AKT signaling, as well as enhanced mitochondrial adenosine triphosphate (ATP) production in HD cells. The value of these findings lies in the converging evidence from behavioral, imaging, and cellular pathology measures. Beyond improved motor performance, changes in brain atrophy and aggregation of the disease-causing protein provide a more concrete basis for investigating a potential disease-modifying effect. The poster also presented results from a Phase I clinical study of MT200605 in healthy adults. The study used a single-center, randomized, double-blind, placebo-controlled design and comprised single ascending dose (SAD) and multiple ascending dose (MAD) stages. No serious adverse events, deaths, or withdrawals due to adverse events were reported. Drug-related adverse events were all mild and self-limiting. Pharmacokinetic results showed that drug exposure increased with dose, with no appreciable accumulation after multiple doses and an overall predictable pharmacokinetic profile. These results provide a safety and pharmacokinetic foundation for subsequent clinical studies in patient populations. TrkB Signaling Provides a Basis for Extending Development from Acute Brain Injury to Neurodegenerative Diseases A defining feature of MT200605's mechanism is its pharmacological modulation of the brain-derived neurotrophic factor (BDNF)/TrkB neurotrophic signaling pathway. This pathway contributes to neuronal survival, synaptic maintenance, and mitochondrial stability, providing an important biological basis for neuroprotection and the preservation of function. MT200605's pharmacological design reportedly combines agonism of the BDNF/TrkB pathway with attenuation of oxidative stress and relief of microcirculatory impairment caused by calcium ion-induced contraction of vascular smooth muscle. The development rationale is to explore more comprehensive neuroprotection by intervening in multiple components of the injury process. From a mechanistic perspective, targeting TrkB provides a rationale for extending MT200605's development into chronic neurodegenerative diseases. Although the pathogenic processes of stroke and Huntington's disease differ substantially, neuronal injury, loss of function, and insufficient neurotrophic support offer points of entry for research across diseases. The findings across multiple measures in the HD model provide new experimental support for this direction. Positive Phase II Stroke Results Show a Significant Reduction in Disability and Potential for Renal Protection MT200605 has completed a Phase II clinical trial in acute ischemic stroke. The multicenter, randomized, double-blind, placebo-controlled study enrolled 360 participants. The primary efficacy endpoint was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days after stroke onset. Results disclosed by the company show that the proportions of patients achieving favorable functional outcomes in both the medium- and high-dose groups were higher than in the placebo group, demonstrating a treatment advantage rarely seen among drugs in this class. For the high-dose group, achieving an mRS score of 0-1 corresponded to an increase of more than 100% in the odds of functional recovery versus placebo, as reflected by the odds ratio (OR). In terms of clinical benefit, approximately one additional patient moved from "requiring assistance" to "being able to live largely independently" for every six patients treated. Over decades of neuroprotective drug development, agents demonstrating such a marked difference in functional outcomes versus placebo in a randomized controlled trial have been exceptionally rare. The difference between the high-dose group and placebo was statistically significant, and the study showed a clear dose-response relationship. The study also observed a trend toward early neurological recovery in the high-dose group, with no serious adverse events related to the investigational drug. For stroke-associated acute kidney injury (AKI), the study also observed a trend toward a dose-dependent reduction in incidence, providing exploratory clinical evidence for further research into the mechanism of "dual brain and kidney protection." The design rationale for this dual protection was validated in the Phase II trial: MT200605 significantly reduced disability and showed the potential to lower AKI incidence in patients with AIS in a dose-dependent manner. AKI incidence in the high-dose group was more than 80% lower than in the placebo group. This result addresses the existing therapeutic gap in preventing AKI in patients with AIS. Neurological Recovery and Combined Brain and Kidney Protection Offer the Potential to Fill a Therapeutic Gap Currently, no neuroprotective drug for AIS has a Class I recommendation supported by Level A evidence in Chinese clinical guidelines. Most marketed agents have Class II recommendations supported by Level B evidence. Mainstream neuroprotective drugs in China include butylphthalide, edaravone, and edaravone dexborneol. Their mechanisms are generally limited to blocking injury through one or two targets, without a mechanistic design that simultaneously promotes neural repair, and none has demonstrated a statistically significant difference in long-term functional outcomes such as those measured by the mRS. Butylphthalide has a research foundation in neuroprotection involving multiple targets. The randomized BAST trial enrolled 1,216 patients with acute ischemic stroke who received intravenous thrombolysis and/or endovascular treatment. Favorable functional outcomes at 90 days were achieved by 56.7% of patients in the butylphthalide group and 44.0% in the placebo group. The endpoint used different mRS thresholds according to baseline stroke severity, providing evidence for combining neuroprotection with reperfusion treatment. Edaravone's principal pharmacological action is free radical scavenging, while edaravone dexborneol extends antioxidant and anti-inflammatory intervention through a combination formulation. In the Phase III TASTE study involving 1,165 patients, the proportions achieving an mRS score of ≤1 at 90 days were 67.18% in the edaravone dexborneol group and 58.97% in the edaravone group. Edaravone dexborneol was superior to edaravone, with a statistically significant difference. The research indicates that MT200605's differentiation should not be reduced to a simple numerical comparison of efficacy with existing agents. The more relevant question to follow is whether the TrkB neurotrophic pathway can translate the functional outcome signals observed in patients with AIS into clinical benefits in chronic neurodegenerative diseases. As a first-in-class (FIC) investigational drug, MT200605 has completed clinical proof of concept. Its effect size far exceeds that of other neuroprotective agents, and it has the potential to become the first treatment in this field to receive high-level recommendations as a first-line option in both Chinese and international clinical guidelines. Another "silent killer" can emerge following stroke: acute kidney injury (AKI). Approximately 19% of patients with AIS develop AKI, and the risk of in-hospital death among patients with AKI is around two to three times that of patients without AKI. Product labeling for approved mainstream neuroprotective drugs advises caution or contraindicates use in patients with impaired renal function or severe renal failure. As a result, precisely those stroke patients facing a higher risk of death are excluded from treatment. A further reason to follow MT200605 is that, alongside the positive signals for 90-day functional outcomes in the AIS Phase II trial, the company has disclosed a new area of investigation: renal protection after stroke. According to Micot Pharma's announcement, AKI incidence in the high-dose group was approximately 80% lower than with placebo in the Phase II data. This means that MT200605 is currently the world's only investigational neuroprotective drug with the potential to specifically prevent and treat post-stroke AKI, and the only agent in this class that could potentially be approved and used with a "renal protection" claim in its labeling. MT200605's ability to protect both the brain and kidneys is closely linked to its distinctive mechanism of action. TrkB receptors are expressed not only in brain tissue but also in renal podocytes, renal tubular epithelial cells, and the juxtaglomerular apparatus. Their activation can stabilize the podocyte cytoskeleton, inhibit renal tubular epithelial cell apoptosis by counteracting endoplasmic reticulum stress through PI3K/AKT signaling, and activate antioxidant defenses through the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2), an important target of neuroprotective drugs. A single molecule protects two organs affected by stroke. The protective pathways in the brain and kidneys share the core PI3K/AKT signaling cascade, disrupting at its origin the vicious cycle of brain injury leading to AKI, worsening renal function, and further aggravation of brain injury. The MDS presentation and AIS Phase II topline results are therefore complementary. The former expands MT200605's international scientific visibility and the scope of its HD research, while the latter provides a translational foundation in patient functional outcomes. For a biopharmaceutical company focused on innovative medicines, a development program built around one mechanism, multiple disease settings, and progressively accumulating evidence at different levels often has greater scope for expansion than an early-stage narrative centered on a single indication. Conclusion In the near term, MDS 2026 has given Micot Pharma an international platform to present its research in movement disorders. Over the medium to long term, the program's value as a platform will depend on whether the company can continue to use verifiable clinical data to translate the potential of the TrkB mechanism across different disease settings into benefits for patients. For the capital markets, this is the central rationale for continuing to follow MT200605's development.
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract CancerSecond FDA Fast Track Designation for Opamtistomig Underscores Its Potential in Immunologically Cold Tumors
- InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in ChinaICP-B161 delivers an extended half‑life, which allows for less frequent dosing and supports subcutaneous administration.
- ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- AARD 截止日期通知：知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人，應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARD事由：全球投資人權益律師事務所 Rosen Law Firm 提醒 Aardvark Therapeutics, Inc. (NASDAQ: AARD) 的下列證券購買人，應注意 2026 年 10 月 13 日的重要首席原告提名期限：(i) 依據 Aardvark 於 2025 年 2 月 13 日首次公開發行（「IPO」）時所發布的註冊聲明及公開說明書（合稱「註冊聲明」）發行，及／或可追溯至該等文件的普通股；及／或 (ii) 於 2025 年 2 月 13 日至 2026 年 5 月 14 日期間（含首尾兩日；以下稱「集體訴訟期間」）購買的證券。
- First Tracks Biotherapeutics IncFirst Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.